Literature DB >> 16770642

Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure.

Anna Sapino1, Caterina Marchiò, Rebecca Senetta, Isabella Castellano, Luigia Macrì, Paola Cassoni, Giampiero Ghisolfi, Milena Cerrato, Enrico D'Ambrosio, Gianni Bussolati.   

Abstract

We propose multicore tissue microarray (TMA) as an alternative to whole section for routine assessment of prognostic factors in breast cancer. Since 2004, we introduced the multicore TMA for testing estrogen (ER) and progesterone receptors (PR), proliferation activity by Ki67, and HER2 overexpression and amplification in routine work. At least four tumor foci were selected on the whole section, and a dedicated technician used a stereomicroscope for accurate sampling of the selected areas. To identify a specific case in the TMA, a separate file and a computerized reporting form with the TMA map were created. A preliminary pilot study comparing the TMA results with those obtained on whole sections showed the specificity of the procedure. Moreover, in everyday diagnosis, hormone receptors were repeated on full section when negative in TMA, without significant discrepancy. Retrospective analysis of the 237 breast carcinomas studied by TMA showed the expected correspondence of tumor-grade differentiation with the hormone receptor pattern, the proliferation activity, and HER2 immunohistochemical and FISH values. In conclusion, multicore TMA may be an efficient approach in the routine study of prognostic factors in breast cancer, significantly reducing costs, time, and burden of slides necessary to accomplish these mandatory tests.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16770642     DOI: 10.1007/s00428-006-0233-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

Review 1.  Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.

Authors:  L Bubendorf; A Nocito; H Moch; G Sauter
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

2.  Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.

Authors:  Priti Lal; Lee K Tan; Beiyun Chen
Journal:  Am J Clin Pathol       Date:  2005-04       Impact factor: 2.493

3.  Tissue microarrays (TMAs) for high-throughput molecular pathology research.

Authors:  A Nocito; J Kononen; O P Kallioniemi; G Sauter
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

4.  High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.

Authors:  Dalia M Abd El-Rehim; Graham Ball; Sarah E Pinder; Emad Rakha; Claire Paish; John F R Robertson; Douglas Macmillan; Roger W Blamey; Ian O Ellis
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

5.  Validation of tissue microarray technology in breast carcinoma.

Authors:  R L Camp; L A Charette; D L Rimm
Journal:  Lab Invest       Date:  2000-12       Impact factor: 5.662

6.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

7.  Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC.

Authors:  R Leake; D Barnes; S Pinder; I Ellis; L Anderson; T Anderson; R Adamson; T Rhodes; K Miller; R Walker
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

8.  Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains.

Authors:  A Sapino; Z Coccorullo; P Cassoni; G Ghisolfi; P Gugliotta; M Bongiovanni; R Arisio; P Crafa; G Bussolati
Journal:  Histopathology       Date:  2003-10       Impact factor: 5.087

9.  Validation of tissue microarray technology in ovarian carcinoma.

Authors:  Daniel G Rosen; Xuelin Huang; Michael T Deavers; Anais Malpica; Elvio G Silva; Jinsong Liu
Journal:  Mod Pathol       Date:  2004-07       Impact factor: 7.842

10.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

View more
  20 in total

Review 1.  Tissue microarrays in clinical oncology.

Authors:  David Voduc; Challayne Kenney; Torsten O Nielsen
Journal:  Semin Radiat Oncol       Date:  2008-04       Impact factor: 5.934

2.  Cell and tissue microarray technologies for protein and nucleic acid expression profiling.

Authors:  Marina Cardano; Giuseppe R Diaferia; Maurizio Falavigna; Chiara C Spinelli; Fausto Sessa; Pasquale DeBlasio; Ida Biunno
Journal:  J Histochem Cytochem       Date:  2012-11-19       Impact factor: 2.479

Review 3.  Tumour heterogeneity: principles and practical consequences.

Authors:  Giorgio Stanta; Stephan Wenzel Jahn; Serena Bonin; Gerald Hoefler
Journal:  Virchows Arch       Date:  2016-07-13       Impact factor: 4.064

4.  Investigation of β-catenin and E-cadherin expression in Dukes B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer?

Authors:  László Tóth; Csilla András; Csaba Molnár; Miklós Tanyi; Zoltán Csiki; Péter Molnár; János Szántó
Journal:  Pathol Oncol Res       Date:  2012-04       Impact factor: 3.201

5.  Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.

Authors:  Maria Vassilakopoulou; Fabio Parisi; Summar Siddiqui; Allison M England; Elizabeth R Zarella; Valsamo Anagnostou; Yuval Kluger; David G Hicks; David L Rimm; Veronique M Neumeister
Journal:  Lab Invest       Date:  2014-11-24       Impact factor: 5.662

6.  Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

Authors:  Veronique M Neumeister; Valsamo Anagnostou; Summar Siddiqui; Allison Michal England; Elizabeth R Zarrella; Maria Vassilakopoulou; Fabio Parisi; Yuval Kluger; David G Hicks; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2012-10-22       Impact factor: 13.506

7.  Limitations of tissue microarrays compared with whole tissue sections in survival analysis.

Authors:  M Haysam Khouja; Mark Baekelandt; Agkha Sarab; Jahn M Nesland; Ruth Holm
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

8.  Safe transportation of formalin-fixed liquid-free pathology specimens.

Authors:  J Metovic; L Bertero; C Musuraca; F Veneziano; L Annaratone; S Mariani; P Cassoni; G Bussolati; Mauro Papotti
Journal:  Virchows Arch       Date:  2018-06-02       Impact factor: 4.064

9.  Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications.

Authors:  Marco Volante; Ida Rapa; Jasna Metovic; Francesca Napoli; Cristian Tampieri; Eleonora Duregon; Massimo Terzolo; Mauro Papotti
Journal:  J Pers Med       Date:  2021-05-06

10.  Tissue microarray design and construction for scientific, industrial and diagnostic use.

Authors:  Daniela Pilla; Francesca M Bosisio; Roberto Marotta; Stefano Faggi; Paolo Forlani; Maurizio Falavigna; Ida Biunno; Emanuele Martella; Pasquale De Blasio; Simone Borghesi; Giorgio Cattoretti
Journal:  J Pathol Inform       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.